Form 4: PepGen Inc. Chief Medical Officer Michelle Mellion Executes Stock Option and Sells Shares Under 10b5-1 Plan

Michelle Mellion, Chief Medical Officer of PepGen Inc., exercised stock options and sold shares of common stock on July 18, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On July 18, 2024, Michelle Mellion, the Chief Medical Officer of PepGen Inc., executed a transaction involving the company's stock.
• Mellion exercised stock options to acquire 12,625 shares of common stock at a price of $10.21 per share.
• Simultaneously, Mellion sold 12,625 shares of common stock at a weighted average price of $18.2023 per share, with individual sales ranging from $18.00 to $18.56.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on January 19, 2024.
• Following these transactions, Mellion directly owns 57,772 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing plan. There's no indication of positive or negative sentiment towards the company's prospects.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Industry Context

Form 4 filings are standard disclosures required by the SEC when corporate insiders, such as officers and directors, trade their company's stock. These filings provide transparency into insider transactions and are closely monitored by investors for insights into management's perspective on the company's value and prospects.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for publicly traded companies in the United States, ensuring transparency of insider transactions.
• The use of a 10b5-1 trading plan is a common practice among corporate insiders to manage their stock transactions while avoiding accusations of insider trading, similar to practices at companies like Pfizer or Amgen where executives routinely use such plans.
• The reported price range of $18.00 to $18.56 for the shares sold is within a typical range for stock transactions of biotech companies of similar size and market capitalization to PepGen Inc.

Stakeholder Impact

• The transactions may have a minor impact on shareholders as they provide insight into insider activity, but the pre-arranged nature of the trading plan mitigates concerns about opportunistic trading.

Key Dates